The Innovators Working to Make in Vivo Cell Therapy a Reality

Why It Matters

In‑vivo cell therapies could eliminate complex cell processing, lowering costs and expanding access, while reshaping the competitive landscape of gene‑ and cell‑based medicines.

Key Takeaways

• AstraZeneca bought EsoBiotec for $1 bn to secure in‑vivo CAR‑T
• Eli Lilly paid $2.4 bn for Orna, accelerating its gene‑therapy pipeline
• Phase I trial showed four responses, three complete remissions in multiple‑myeloma
• Key technical hurdles: dosing accuracy, off‑target effects, immunogenicity
• Suppliers like Lonza and LEON develop modular LNP platforms for personalized batches

Pulse Analysis

In‑vivo cell therapy represents a hybrid of gene‑editing and cell‑based medicine, where therapeutic genes are delivered directly into a patient’s body rather than being engineered ex vivo. By using viral vectors or lipid‑nanoparticle (LNP) carriers, the approach sidesteps the logistical nightmare of harvesting, modifying, and cryopreserving live cells. Early clinical data, such as the Phase I multiple‑myeloma study that reported four objective responses and three complete remissions, suggest the modality can achieve efficacy comparable to traditional CAR‑T while potentially offering an off‑the‑shelf solution.

The sector’s momentum is reflected in a wave of billion‑dollar acquisitions: AstraZeneca’s $1 bn purchase of EsoBiotec and Eli Lilly’s $2.4 bn deal for Orna Therapeutics signal that large pharmaceutical players are betting on the technology despite limited trial readouts. At the same time, CDMOs and device innovators are racing to solve core challenges—precise dosing, off‑target delivery, and immune reactions. Lonza is consolidating supply chains for ionisable lipids used in LNPs, while companies like LEON provide single‑patient “scale‑out” manufacturing devices, reducing the need for large‑scale batch production.

Regulatory bodies still classify in‑vivo therapies under the broader gene‑therapy umbrella, creating a gray area for developers. Nonetheless, the promise of eliminating complex cell handling could dramatically cut production costs and broaden patient access, especially for autologous indications that have struggled commercially. Investors are watching closely; the next 12 months of data will determine whether in‑vivo cell therapies become a complementary pillar to ex‑vivo platforms or evolve into a standalone therapeutic class.